We are live on ! Find out more
RKDA icon

Arcadia Biosciences
RKDA

13 hedge funds and large institutions have $465K invested in Arcadia Biosciences in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,143% more capital inflows, than outflows

Capital inflows: $109K | Capital outflows: $4.84K

1.77% more ownership

Funds ownership: 3.96% → 5.73% (+1.8%)

0% more funds holding

Funds holding: 13 → 13 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
13
Holders Change
–
Holders Change %
0%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$56.4K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$50.6K
3
Atticus Wealth Management
Atticus Wealth Management
Florida
+$1.12K

Top Sellers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$4.82K
2
US Bancorp
US Bancorp
Minnesota
-$14
3
Oliver Lagore Vanvalin Investment Group
Oliver Lagore Vanvalin Investment Group
Michigan
-$11

RKDA Hedge Fund Activity: Q4 2024 in Review

13 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q4 2024, worth a combined $465K — up 212% from $149K a quarter earlier.

Fund positioning in RKDA was balanced in Q4 2024: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $56.4K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $4.82K sold.

  • 13 institutional investors held Arcadia Biosciences (RKDA) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $465K of Arcadia Biosciences stock for Q4 2024, up 212% quarter-over-quarter.
  • 3 funds opened new Arcadia Biosciences positions in Q4 2024 and 3 closed out, a net change of 0 holders.
  • The largest Arcadia Biosciences buyer in Q4 2024 was UBS Group, an estimated $56.4K added.
  • The largest Arcadia Biosciences seller in Q4 2024 was Tower Research Capital (TRC), an estimated $4.82K sold.

Based on aggregated 13F filings for Q4 2024.